Trifluridine and tipiracil for the treatment of advanced colorectal cancer – case report


MUDr. Stanislav John

Klinika onkologie a radioterapie LF UK a FN Hradec Králové



The treatment of colorectal cancer in the first two lines is based on a combination of chemotherapy (FOLFOX and FOLFIRI, also in variations) and biological therapy in the form of vascular endothelial growth factor (VEGF) and epidermal growth factor (EGFR) inhibitors. Although this therapy is challenging and brings a lot of side effects, many patients are in good condition after progression. Especially for these patients the treatment with trifluridine/tipiracil is appropriate. This preparation contains a nucleoside analogue trifluridine and a thymidine phosporylase inhibitor tipiracil - inhibitor of the enzyme metabolizing just that nucleoside analogue. Trifluridine/tipiracil demonstrated efficacy in phase 3 clinical trial RECOURSE.1 Based on that the treatment was approved as well in the Czech Republic.


Key words

colorectal cancer, chemotherapy, biological therapy, trifluridine/tipiracil



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...